leflunomide has been researched along with Coronavirus Infections in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| "A case with rheumatoid arthritis and insufficient compensation under disease-modifying combined long-term therapy with methotrexate and leflunomide is reported." | 3.96 | [Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy]. ( Lange, U; Müller-Ladner, U; Steinchen, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Steinchen, N | 1 |
| Müller-Ladner, U | 1 |
| Lange, U | 1 |
| Cai, S | 1 |
| Sun, W | 1 |
| Li, M | 1 |
| Dong, L | 1 |
| Coelho, AR | 1 |
| Oliveira, PJ | 1 |
| Xiong, R | 1 |
| Zhang, L | 1 |
| Li, S | 1 |
| Sun, Y | 1 |
| Ding, M | 1 |
| Wang, Y | 1 |
| Zhao, Y | 1 |
| Wu, Y | 1 |
| Shang, W | 1 |
| Jiang, X | 1 |
| Shan, J | 1 |
| Shen, Z | 1 |
| Tong, Y | 1 |
| Xu, L | 1 |
| Chen, Y | 1 |
| Liu, Y | 1 |
| Zou, G | 1 |
| Lavillete, D | 1 |
| Zhao, Z | 1 |
| Wang, R | 1 |
| Zhu, L | 1 |
| Xiao, G | 1 |
| Lan, K | 1 |
| Li, H | 1 |
| Xu, K | 1 |
1 review available for leflunomide and Coronavirus Infections
| Article | Year |
|---|---|
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
3 other studies available for leflunomide and Coronavirus Infections
| Article | Year |
|---|---|
[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].
Topics: Antibodies, Viral; Arthritis, Rheumatoid; Betacoronavirus; Biological Therapy; Coronavirus Infection | 2020 |
Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
Topics: Antiviral Agents; Betacoronavirus; Biphenyl Compounds; Coronavirus Infections; COVID-19; COVID-19 Dr | 2020 |
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Topics: Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Cell Line; Coronavirus Infections; COVID- | 2020 |